Equitable Holdings
EQH
$56.12
+1.59%
Equitable Holdings, Inc. is a diversified financial services holding company that provides retirement, asset management, and wealth management solutions to individual and institutional clients through three segments: Retirement (annuities, retirement savings plans, and spread lending), Asset Management (operated through AllianceBernstein, or AB), and Wealth Management (advisory accounts, financial planning, life insurance, and annuities). The company is a scaled, established player in the U.S. retirement and protection market rather than a disruptor, with its competitive identity anchored in the complementary pairing of a capital-intensive spread-lending annuity book and a fee-based asset management franchise that diversifies earnings away from pure interest-rate sensitivity. The current investor narrative centers on a sharp earnings recovery and capital-return story: after a deeply loss-making stretch in 2025 driven by derivative and mark-to-market volatility, EQH posted a strong Q3 2026 EPS beat (diluted EPS of $4.05 versus a year-ago loss of $4.47), and management has paired that rebound with aggressive buybacks and a meaningful dividend. The debate now hinges on whether the improved profitability is durable — the Q3 revenue and AUM metrics came in below expectations, leaving the stock range-bound near its highs as investors weigh buyback-driven EPS tailwinds against uneven top-line and asset-gathering momentum.…
EQH
Equitable Holdings
$56.12
Related headlines
Investment Opinion: Should I buy EQH Today?
Rating: Buy (accumulate on strength, size for volatility). The core thesis is that EQH is a recovered-earnings, capital-return story trading at a deep 6.20x forward PE on estimated EPS of $11.85, with a unanimous analyst consensus of strong_buy (11 Buy, 1 Hold, 0 Sell) and an average target of $64.00 implying 15.9% upside from $55.24 — and even the $58.00 low target sits 5.0% above the market. The stock is not cheap because the franchise is broken; it is cheap because the market has not yet re-rated it for the Q3 2026 swing from a -$4.47 loss to $4.05 diluted EPS.
Four data points anchor the rating. First, valuation: 6.20x forward PE, 1.22x PS and 0.58x EV/Sales against an 18.65% ROE and a 2.64% dividend yield, with the PS ratio near the low end of its historical 2.47x–10.62x band. Second, profitability: Q3 2026 net income of $1.186 billion (30.56% net margin), operating income of $1.443 billion (37.18% margin) and an 88.77% gross margin. Third, capital return: $366 million of buybacks and $96 million of dividends in Q2 2026 alone, funded by $643 million of quarterly operating cash flow and $1.395 billion of TTM free cash flow, with diluted shares down from 303.2 million to 273.4 million year-over-year. Fourth, momentum: +28.91% over six months versus +3.11% for SPY, a 25.80-point relative-strength spread, and a price at roughly 94% of its 52-week range.
The risks that could invalidate this are (1) revenue and AUM keep missing — Q3 revenue grew just 1.68% year-over-year and came in below expectations, so the EPS beat is buyback- and mark-driven rather than organic; (2) another mark-to-market loss quarter like Q2 2026's -$453 million net loss resets the earnings base and the forward estimate; and (3) the stock is extended, sitting 2.4% below its $56.57 high with roughly 36% downside to the $35.195 52-week low. The rating would upgrade to a higher-conviction Buy on a clean breakout above $56.57 accompanied by positive AB net flows and revenue growth above 5%; it would downgrade to Hold if revenue growth stays below 2% for two more quarters or if the $11.85 EPS estimate is cut toward the $10.70 low end. Verdict: undervalued relative to its own history and to its recovered earnings power, but fairly-to-fully valued relative to near-term momentum — a value-with-catalyst position, not a bargain-bin one.
Sign up to view all
EQH 12-Month Price Forecast
The forward view is constructive but not complacent: EQH offers a 6.20x forward multiple, an 18.65% ROE, a 2.64% dividend yield and $1.395 billion of TTM free cash flow, all supported by a unanimous strong_buy consensus whose lowest target ($58.00) is still above the current $55.24. The problem is quality of earnings — revenue grew only 1.68% year-over-year and AUM missed, so the Q3 EPS swing from -$4.47 to $4.05 rests on buybacks and favorable marks rather than organic expansion, and quarterly net income has ranged from $1.186 billion to -$453 million within three quarters. The stock's position at roughly 94% of its 52-week range means the optimistic side is partly priced, which is why the base case (50% probability, $58–$64) is a grind rather than a re-rating. I would upgrade to high confidence on a breakout above $56.57 paired with positive AB net flows and revenue growth above 5%; I would downgrade to neutral if revenue growth stays below 2% for two more quarters or the $11.85 EPS estimate is cut toward $10.70.
Wall Street consensus
Coverage is robust and overwhelmingly bullish: 11 analysts rate the stock, with 11 Buy, 1 Hold, and 0 Sell, producing a consensus recommendation of "strong_buy" and a recommendation mean of 1.33 (where 1.0 is a strong buy). The average target price of $64.00 implies roughly 15.9% upside from the current $55.24, and even the low target of $58.00 sits about 5.0% above the current price — meaning every published target is above the market, an unusually uniform signal of conviction. The consensus clearly leans bullish, supported by a steady stream of reiterated Outperform/Overweight/Buy ratings from Wells Fargo, Barclays, Mizuho, Evercore ISI, KBW, and Jefferies through 2026.
The target range of $58.00 to $68.00 is relatively tight (about 17% between low and high), signaling strong analyst conviction rather than deep disagreement. The high target of $68.00 (roughly 23% upside) likely assumes the Q3 earnings recovery proves durable, buybacks continue to shrink the share count, and the AB asset-management franchise resumes net inflows that lift fee revenue and drive multiple expansion. The low target of $58.00 still implies upside and appears to price in a more conservative scenario — flat AUM, continued quarterly earnings volatility, and no re-rating — rather than a bear case. Notably, the institutional ratings log shows only reiterations and no downgrades, and the estimated EPS average of $11.85 (range $10.70–$12.63) versus estimated revenue of $17.95 billion underpins the bullish stance; the main risk to targets is that revenue and AUM keep missing even as EPS beats, which could cap multiple expansion.
Bulls vs Bears: EQH Investment Factors
The bull case currently has the stronger evidence: unanimous analyst support with every target above the market, a genuine earnings recovery (Q3 EPS of $4.05 versus -$4.47 a year ago), a 6.20x forward PE, an 18.65% ROE, and accelerating relative strength of 25.80 points over six months. The bear case is not about the franchise deteriorating but about quality of earnings — revenue grew just 1.68% year-over-year, AUM missed, and quarterly results swing from a $621 million profit to a $453 million loss to a $1.186 billion profit, meaning the forward EPS estimate carries real execution risk. The single most important tension is whether the Q3 profitability is durable: if revenue and net inflows at AllianceBernstein reaccelerate, the 6.20x multiple re-rates toward the $64–$68 targets; if top-line misses persist, buybacks alone will not sustain the multiple and the stock likely stalls near $56. The stock's position at 94% of its 52-week range means the market has already begun to price the optimistic side of that debate, tilting near-term risk/reward toward neutral even with a bullish fundamental skew.
Bullish
- Unanimous analyst conviction, all targets above price: All 11 covering analysts rate EQH Buy (11 Buy, 1 Hold, 0 Sell) with a recommendation mean of 1.33 and a consensus of strong_buy. The average target of $64.00 implies 15.9% upside from $55.24, and even the low target of $58.00 sits 5.0% above the current price — every published target is above the market, an unusually uniform signal.
- Earnings recovery is dramatic and margin-rich: Q3 2026 diluted EPS of $4.05 versus a year-ago loss of $4.47, with net income of $1.186 billion (30.56% net margin) and operating income of $1.443 billion (37.18% operating margin). Gross margin of 88.77% in the quarter shows the underlying franchise economics remain strong once mark-to-market noise is stripped out.
- Deep value on forward earnings: Forward PE of 6.20x against estimated EPS of $11.85, PS of 1.22x and EV/Sales of 0.58x are low absolute multiples for a financial with an 18.65% ROE and 2.64% dividend yield. The current 1.22x PS sits near the low end of the historical 2.47x–10.62x band, suggesting the market has not re-rated the stock for recovered profitability.
- Aggressive capital return shrinking share count: Management repurchased $366 million of stock and paid $96 million of dividends in Q2 2026 alone, funded by $643 million of quarterly operating cash flow, with TTM free cash flow of $1.395 billion. Diluted shares fell from 303.2 million in Q3 2025 to 273.4 million in Q3 2026, a mechanical EPS tailwind that compounds the earnings recovery.
Bearish
- Revenue and AUM misses undercut the EPS beat: Q3 2026 revenue of $3.881 billion grew only 1.68% year-over-year and came in below expectations, alongside soft AUM metrics. The EPS beat is being driven by buybacks and marks rather than top-line momentum, which is why the stock has stayed range-bound near its highs despite the headline beat.
- Earnings are violently volatile quarter to quarter: The quarterly progression — Q1 2026 net income of $621 million, Q2 a $453 million loss (EPS -$1.67), Q3 a $1.186 billion profit — shows earnings are hostage to market and actuarial marks. Trailing net margin is -11.83% and trailing EPS is -$0.097, so the 6.20x forward PE rests entirely on the $11.85 estimate materializing.
- Stock is extended with little margin of safety: At $55.24 the stock is 57% above its 52-week low of $35.195 and within 2.4% of its 52-week high of $56.57, leaving only about 2.4% to resistance versus roughly 36% downside to the annual low. The -30.92% max drawdown on record shows how sharply insurance equities can gap on rate and credit shocks.
- Balance-sheet gauges are distorted and unhelpful: A current ratio of 0.565, negative debt-to-equity of -88.68 and P/B of -191.95 reflect accumulated losses and heavy buybacks that have eroded book equity. Traditional leverage and liquidity screens are effectively unusable, forcing investors to rely on regulatory capital and holding-company cash disclosures that are not in the provided data.
EQH Technical Analysis
EQH is in a sustained, well-defined uptrend, with the stock up 13.22% over the past year and 28.91% over six months, and the current price of $55.24 sitting at roughly 94% of its 52-week range ($35.195 low to $56.57 high). That positioning near the top of the annual range signals genuine momentum rather than a value bounce, though it also means the stock is extended and offers limited near-term margin of safety for new entries. The 52-week low of $35.195 implies the stock has recovered more than 57% from its trough, confirming a durable trend reversal rather than a dead-cat bounce.
Short-term momentum is accelerating and decisively outpacing the broader market: the stock is up 4.94% over the past month versus a -1.99% decline in SPY (a 6.93-point relative-strength spread), 7.68% over three months versus -2.01% for SPY (9.69 points of relative strength), and 15.16% year-to-date versus 10.62% for the index. The 1-month trend (+4.94%) is directionally consistent with the 1-year trend (+13.22%) but steeper, indicating momentum is building rather than diverging — a healthy pattern that typically supports continuation. The most recent session added 1.81% on volume of roughly 4.22 million shares, and the stock closed at $55.24 versus a $54.26 prior close, putting it within about 2.4% of its 52-week high.
Key technical resistance sits at the 52-week high of $56.57; a clean breakout above that level would confirm the uptrend and likely invite momentum-driven flows, while failure there could set up a double-top consolidation. Support is anchored at the 52-week low of $35.195, with intermediate support likely in the high-$40s where the stock consolidated in August and September (roughly $48–$50). With a beta of 1.049, EQH is only about 5% more volatile than the market — modest for a financial — which supports standard position sizing, though the -30.92% max drawdown on record is a reminder that insurance-linked equities can gap sharply on rate and credit shocks.
Beta
—
—
Max Drawdown
-30.9%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+14.9%
Cumulative gain past year
| Period | EQH Return | S&P 500 |
|---|---|---|
| 1m | +3.9% | -1.0% |
| 3m | +7.6% | -0.2% |
| 6m | +31.7% | +4.0% |
| 1y | +14.9% | +13.6% |
| ytd | +17.0% | +12.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EQH Fundamental Analysis
Revenue is growing but unevenly: Q3 2026 revenue of $3.881 billion rose 1.68% year-over-year, a modest pace that masks significant quarterly volatility — Q1 2026 revenue was $4.23 billion, Q2 collapsed to $1.658 billion amid a $453 million net loss, and Q3 rebounded sharply. The year-over-year comparison is flattered by a very weak prior-year base (Q3 2025 revenue of just $1.45 billion and a -$1.309 billion net loss), so the underlying growth trajectory is better described as stabilizing than accelerating. The Retirement segment remains the dominant revenue engine, while the Asset Management (AB) franchise provides fee-based diversification; the Q3 revenue miss and soft AUM metrics suggest asset gathering is not yet firing on all cylinders, which is the key swing factor for the investment case.
Profitability has swung dramatically back into the black: Q3 2026 net income was $1.186 billion (a 30.56% net margin) versus a -$1.309 billion loss in Q3 2025, and gross margin was a strong 88.77% with operating income of $1.443 billion (37.18% operating margin). The quarterly progression — Q1 2026 net income of $621 million, Q2 of -$453 million, Q3 of $1.186 billion — shows earnings are highly sensitive to market and actuarial marks rather than a smooth compounding stream, which is typical of annuity-heavy insurers but complicates margin analysis. The trailing metrics reflect this whipsaw: trailing net margin is -11.83% and trailing EPS is -$0.097, even as the forward picture (estimated EPS of $11.85) implies a dramatic normalization.
Balance-sheet and cash-flow signals are mixed but generally supportive of the capital-return thesis: TTM free cash flow is $1.395 billion, ROE is a strong 18.65%, and the dividend yield of 2.64% is well covered by earnings power. However, the current ratio of 0.565 and a negative debt-to-equity ratio of -88.68 (an artifact of negative or near-zero book equity from accumulated losses and buybacks) mean traditional leverage and liquidity gauges are unreliable here — investors should focus on regulatory capital and holding-company cash instead. Management is returning substantial capital, with $366 million of stock repurchased and $96 million of dividends paid in Q2 2026 alone, funded by operating cash flow of $643 million that quarter; the sustainability of that pace depends on the earnings recovery holding.
Quarterly Revenue
$3.9B
2026-09
Revenue YoY Growth
+167.7%
YoY Comparison
Gross Margin
88.8%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EQH Overvalued?
Because trailing net income is negative (trailing EPS of -$0.097, trailing PE of -9.87), the PE ratio is not a meaningful anchor; I therefore lead with the price-to-sales ratio of 1.22x and the forward PE of 6.20x. The enormous gap between the negative trailing PE and the 6.20x forward multiple — against estimated forward EPS of $11.85 — tells you the market is pricing a full normalization of earnings and is effectively ignoring the trailing loss as a one-off mark-to-market artifact. The 1.22x PS and 0.58x EV/Sales are low absolute multiples, consistent with a capital-intensive insurer rather than a high-growth asset manager.
Peer comparison is constrained because the provided valuation dataset does not include industry-average multiples, so a precise premium/discount spread cannot be quantified (industry averages: data not available). On an absolute basis, a 6.20x forward PE and 1.22x sales are inexpensive for a financial with an 18.65% ROE and a 2.64% dividend yield, suggesting the market is discounting the durability of the earnings recovery rather than paying up for it. The PEG ratio of 0.044 is extremely low but should be treated with caution given the volatility of the earnings base used in the calculation.
Historically, EQH's own multiples have been wildly unstable — quarterly PE ratios in the historical dataset range from 2.93x (Q3 2026) to 81.39x (Q1 2025) and negative in several loss quarters, while PS ratios have ranged from roughly 2.47x to 10.62x. The current 1.22x PS sits near the low end of that historical band, which could signal either a value opportunity or lingering skepticism about earnings quality; given the strong Q3 beat and buyback support, the more likely read is that the market has not yet fully re-rated the stock for its recovered profitability. The forward PE of 6.20x versus a trailing figure that is negative underscores how much of the valuation depends on the forward earnings estimate materializing.
PE
-9.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 1x~17x
vs. Industry Avg
16.6x
Industry PE ~16.6x*
EV/EBITDA
-85.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality rather than solvency. Quarterly net income swung from $621 million in Q1 2026 to -$453 million in Q2 to $1.186 billion in Q3, and trailing EPS is -$0.097 with a trailing net margin of -11.83%, so the 6.20x forward PE depends entirely on the $11.85 consensus EPS materializing. Revenue growth of just 1.68% year-over-year in Q3, combined with a revenue and AUM miss, means the EPS beat is being manufactured by buybacks ($366 million repurchased in Q2 alone) and favorable marks rather than organic expansion. The current ratio of 0.565 and negative debt-to-equity of -88.68 mean conventional liquidity and leverage metrics offer no real comfort, and the capital-return pace depends on operating cash flow of $643 million per quarter holding up.
Market and competitive risks are dominated by valuation compression and rate sensitivity. With the stock at $55.24, roughly 94% of its 52-week range and only 2.4% below the $56.57 high, there is minimal cushion if momentum reverses; a beta of 1.049 means EQH tracks the market closely, so a broad financials rotation or rate shock transmits almost one-for-one. The asset-management franchise (AllianceBernstein) competes in a fee-compression industry where passive flows pressure active managers, and the Q3 AUM miss suggests EQH is not immune; continued net outflows would cap fee revenue and block the multiple expansion the bull case requires. Recent coverage explicitly frames the quarter as mixed — a strong EPS beat against revenue and AUM misses — which is precisely the kind of narrative that keeps a stock range-bound even as fundamentals improve.
In a worst-case scenario, revenue and AUM keep missing through the next two quarters, the $11.85 forward EPS estimate gets cut toward the $10.70 low end, and the market refuses to re-rate the 6.20x multiple. Combined with a rate or credit shock that forces another mark-to-market loss quarter like Q2 2026, the stock could retest its 52-week low of $35.195, a decline of roughly 36% from $55.24. A less severe but more probable adverse path takes the stock back to the $48–$50 consolidation zone from August–September 2026, about 10–13% below the current price, consistent with the -30.92% max drawdown on record. The analyst low target of $58.00 is not a bear case — it is above the current price — so investors should size positions against the 52-week low, not the published target floor.
FAQ
The most severe risk is earnings volatility: quarterly net income swung from $621 million in Q1 2026 to -$453 million in Q2 to $1.186 billion in Q3, and trailing EPS is -$0.097, so the entire 6.20x forward valuation rests on the $11.85 estimate materializing. Second is top-line stagnation — Q3 2026 revenue grew just 1.68% year-over-year and AUM missed, meaning the EPS beat is manufactured by $366 million of quarterly buybacks and favorable marks rather than organic growth. Third is valuation and momentum risk: at $55.24 the stock is within 2.4% of its $56.57 high with roughly 36% downside to the $35.195 low, and a beta of 1.049 means a broad financials rotation or rate shock transmits almost one-for-one, consistent with the -30.92% max drawdown on record. Fourth is balance-sheet opacity — a current ratio of 0.565 and negative debt-to-equity of -88.68 make conventional leverage and liquidity screens unusable, forcing reliance on regulatory capital disclosures not captured in the headline metrics.
The 12-month forecast splits into three scenarios. The base case carries 50% probability and a $58–$64 range, assuming forward EPS lands near the $11.85 consensus, revenue growth stays in the 1%–4% band, and no repeat of a Q2 2026-style mark-to-market loss — a grind toward the $64.00 average target without a sharp re-rating. The bull case carries 30% probability and a $64–$68 range, requiring revenue growth above 5%, positive AllianceBernstein net flows, and a breakout above the $56.57 high that re-rates the 6.20x multiple toward the $68.00 high target. The bear case carries 20% probability and a $35.195–$50 range, triggered by a second consecutive revenue and AUM miss that cuts the EPS estimate toward $10.70 plus a rate or credit shock forcing another loss quarter. The base case is most likely, and its key assumption is that the Q3 2026 earnings recovery proves durable enough to hold the forward estimate while buybacks and the 2.64% dividend support the price.
The stock looks undervalued on forward earnings but only fairly valued on momentum. The trailing PE of -9.87 is meaningless because trailing EPS is -$0.097, so the relevant anchor is the 6.20x forward PE on estimated EPS of $11.85, alongside a 1.22x PS and 0.58x EV/Sales — low absolute multiples for a financial with an 18.65% ROE and a 2.64% dividend yield. The current 1.22x PS sits near the low end of the historical 2.47x–10.62x band, suggesting the market has not re-rated the stock for its recovered profitability. However, the stock is up 28.91% over six months versus 3.11% for SPY and trades at roughly 94% of its 52-week range, so near-term optimism is already partly priced. The valuation implies the market expects the earnings recovery to hold but does not yet believe it is durable enough to pay a higher multiple — a re-rating toward the $64–$68 targets requires revenue growth above 5% and positive AB net flows.
On a risk/reward basis the setup is favorable but not exceptional. The upside to the $64.00 average analyst target is 15.9% from $55.24, and even the $58.00 low target implies 5.0% upside, meaning all 11 covering analysts see the stock higher — a rare unanimity backed by a 6.20x forward PE and an 18.65% ROE. The downside is real, however: the stock sits within 2.4% of its $56.57 high and roughly 36% above its $35.195 52-week low, so a momentum reversal or another mark-to-market loss quarter like Q2 2026's -$453 million could produce a sharp drawdown. The biggest fundamental caveat is that Q3 2026 revenue grew only 1.68% year-over-year and AUM missed, so the EPS beat is buyback- and mark-driven rather than organic. It is a good buy for value-oriented investors with a 12–18 month horizon who can tolerate earnings volatility and who size the position against the 52-week low rather than the analyst target floor; it is a poor fit for investors needing stable, predictable earnings or low drawdowns.
EQH is better suited to a medium-to-long-term hold than to short-term trading. The fundamental case — a 6.20x forward PE, 18.65% ROE, $1.395 billion of TTM free cash flow, a 2.64% dividend yield and a shrinking share count from 303.2 million to 273.4 million diluted shares year-over-year — needs several quarters to play out, and the analyst targets of $58–$68 are 12-month views. The stock is not a low-volatility compounder, however: beta of 1.049 is only modestly above the market, but the -30.92% max drawdown and the swing from a $1.309 billion loss in Q3 2025 to $1.186 billion of profit in Q3 2026 show earnings visibility is low, which argues against leveraged or concentrated positioning. Short-term traders could work the $56.57 resistance and $48–$50 support range, but the 1.81% single-day move on 4.22 million shares shows the tape can gap on news. A suggested minimum holding period is 12–18 months, long enough to capture at least two more earnings reports and confirm whether revenue growth and AB net flows improve.